Conference abstractPublished 29 May 2017
Liposomes targeted with therapeutic antibodies: a potent tool in anticancer therapy
University of Wrocław, Poland
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Statement of the Problem: Nanoparticle-based drug formulations are expected to be more efficient and less toxic than conventional drug formulations. This is indeed true in case of the most widely used nanoparticles including liposomes, micelles, dendrimers, nanotubes, and polymers. Moreover, most of the nanoparticle-based drug formulations offer a possibility of targeting the drug-loaded vehicles. Such strategy in case of anticancer drugs promises to be a hopeful strategy that allows to reduce toxicity and minimize adverse side effects. Targeting exploits the high affinity of cell-surface-targeted ligands, for specific retention and uptake by the targeted diseased cells. Methodology & Theoretical Orientation: In this short review we would like to point to the application of liposomes as a versatile anticancer therapeutic carrier which can be targeted with antibodies directed against specific surface markers of cancer cells. Long-circulating liposomes containing PEG-PE and chemically activated PEG (e.g. maleimide derivative) may be considered as “Lego blocks”. Combining them with other components (i.e. drugs and surface-exposed molecules) in different configurations opens up multiple possibilities for different formulations of targeted anticancer drugs. They can be directed to specific tumor cells via targeting ligand(s) which could be attached covalently to the surface of liposomes. Prominent, relatively easy to apply as targeting agents are therapeutic antibodies already available on the market. Such liposomes may contain actively or passively encapsulated therapeutics of various nature. Conclusion & Significance: Two types of such nanocarriers were developed in our laboratory. One consists of BCL-2 antisense oligodeoxynucleotide complexed with cationic lipid or polyethyleneimine with anti CD20 antibody and the other is based on simvastatin carrying liposomes targeted with anti HER2 antibody. The former type of formulations fulfill criteria of size, stability, specificity and high efficacy against specific type of cancer cells without obvious side effects in both in vitro and in vivo studies. Liposomal formulation of simvastatin targeted with HER2 antibody proves promising vehicle to deliver relatively high amounts of simvastatin to HER2 overexpressing cells. Acknowledgement The work was supported by grants from: Wroclaw Research Centre EIT+, project:“ Biotechnologies and advanced medical technologies” - BioMed (POIG.01.01.02-02-003/08) co-financed by the EU Operational Programme Innovative Economy,1.1.2) and by National Science Centre, Poland, grant UMO-2016/21/B/NZ7/01070 and by Wroclaw Center of Biotechnology, program The Leading National Research Center (KNOW) for years 2014–2018.
Subjects
Immunology & MicrobiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectImmunology & Microbiology
- BylineArticles whose byline prints “Aleksander F. Sikorski”